CrushSCI.com
242.9Average days
176Median days
97Fastest days
560Longest days
3572025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

97 days

Targeting nucleolin-driven cancer stemness suppresses high-risk neuroblastoma in vivo

Authors
Dan Qi; Ronghu Ke; Euni Wu; Yizhong Pan; S. Stephen Yi; Jason H. Huang; Erxi WuShow moreShow less
Affiliations
Department of Neurosurgery and Neuroscience Institute, Baylor Scott & White Health, Temple, TX 76508, USA; Baylor Research Institute, Baylor Scott & White Health, Temple, TX 76508, USA; Department of Neurosurgery, Baylor College of Medicine, Temple, TX 76508, USA; Department of Electrical and Computer Engineering, Cockrell School of Engineering, The University of Texas at Austin, Austin, TX 78712, USA; Naresh K. Vashisht College of Medicine and Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, TX 77843, USA; Cancer Research Center and Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USAShow moreShow less
Source PDF DOI Publisher page
306 days

ENO1 as a potential tumor prognostic marker promotes the proliferation, invasion, and metastasis of breast cancer cells

Authors
Lifang He; Yue Xu; Lu Huang; Lijuan He; Zexiao Chen; Zhaochang Qi; Yukun CuiShow moreShow less
Affiliations
Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515063, China; Shantou Key Laboratory of Precision Diagnosis and Treatment in Women's Cancer, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515063, China; State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong 511436, China; Guangzhou Morui Pharmaceutical Technology Co., Ltd., Guangzhou Medical University, Guangzhou, Guangdong 511436, China; Precision Oncology Diagnosis and Treatment Centre of Foshan Fosun Chancheng Hospital, Foshan, Guangdong 528031, China; Outpatient Nursing, Hangzhou West Lake Zhijiang Ophthalmology Hospital, Hangzhou, Zhejiang 310000, ChinaShow moreShow less
Source PDF DOI Publisher page
560 days

Ginsenoside Rg1 attenuates mitochondrial dysfunction in bleomycin-induced pulmonary fibrosis by inhibiting Nrf2/Sirt3 pathways

Authors
Qi Qi; Shihao Wen; Linchao Niu; Ru Zhang; Meili Lu; Jingliang Zhang; Hongxin WangShow moreShow less
Affiliations
Key Laboratory of Cardiovascular and Cerebrovascular Drug Research of Liaoning Province, Jinzhou Medical University, Jinzhou, Liaoning 121000, China; Department of Anesthesiology, Jinzhou Central Hospital, Jinzhou Medical University Graduate Training Base, Jinzhou, Liaoning 121000, China; Internal Medicine-Cardiovascular Department, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121000, ChinaShow moreShow less
Source PDF DOI Publisher page
131 days

A candidate PTPN5 frameshift variant in a family with a neurodevelopmental disorder supported by a zebrafish loss-of-function model

Authors
Yunlong Meng; Yu Chen; Xingkun Tang; Kangyu Liu; YanLi Ma; Yuanhai Xie; Zilin Zhong; Jianjun ChenShow moreShow less
Affiliations
Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, Department of Pediatrics, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai 200434, China; Institute of Medical Genetics, Department of Big Data in Health Science, School of Public Health and General Medicine, Tongji University School of Medicine, Tongji University, Shanghai 200331, ChinaShow moreShow less
Source PDF DOI Publisher page
121 days

Genetic engineering of primary human mesenchymal stromal cells using the CRISPR/Cas9 synergistic activation mediator

Authors
M.C. Killer; X. Zhang; T. Adhikary; C. Kasper; A. Neubauer; M. Frech; C. BrendelShow moreShow less
Affiliations
Department of Hematology, Oncology and Immunology, Marburg University, Marburg 35041, Germany; Department of Regenerative Medicine, Tongji University, Shanghai 200092, China; Institute of Molecular Biology and Tumor Research, Marburg University, Marburg 35041, Germany; Department for Biotechnology and Food Technology, BOKU University, Vienna 1180, AustriaShow moreShow less
Source PDF DOI Publisher page
176 days

Robust prediction of response to growth hormone therapy by five PBMC-based transcripts

Authors
Valerie van Kekem; Irene Victoria Bermúdez-Pérez; Alexandra E. Kulle; Maik Welzel; Nadine Hornig; Gerhard Binder; Matthias Hübenthal; Robert Häsler; Paul-Martin HolterhusShow moreShow less
Affiliations
Department of Neurology, University Hospital of Schleswig-Holstein, UKSH, Campus Kiel, Arnold-Heller-Straße 3, Kiel 24105, Germany; Department of Dermatology and Allergy, University Hospital of Schleswig-Holstein, UKSH, Campus Kiel, Arnold-Heller-Straße 3, Kiel 24105, Germany; Department of Pediatrics I, Pediatric Endocrinology and Diabetes, University Hospital of Schleswig-Holstein, UKSH, Campus Kiel, Kiel 24105, Germany; Institute of Clinical Chemistry, UKSH, Kiel/Lübeck 24105, Germany; Private Practice of Pediatrics, Am Ochsenkopf 1, Eckernförde 24340, Germany; Institute of Human Genetics, University Hospital of Schleswig-Holstein, UKSH, Campus Kiel, Kiel 24105, Germany; Pediatric Endocrinology, University Children’s Hospital Tübingen, Tübingen 72076, GermanyShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Genes & Diseases take to review a manuscript?

As of 2026-11-19, CrushSCI has 15 complete review records for Genes & Diseases. The fastest paper went from submission to acceptance in 97 days (Targeting nucleolin-driven cancer stemness suppresses high-risk neuroblastoma in vivo, received 2026-01-21, accepted 2026-04-28); the slowest took 560 days. The average is 242.9 days and the median is 176 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.